José Antonio Casado

Centre for Biomedical Network Research on Rare Diseases — Spain

Biochemistry, Genetics and Molecular Biology · Life Sciences

22h-index3.5kcitations87works6.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

DNA Repair Mechanisms(35), CRISPR and Genetic Engineering(24), Chromosomal and Genetic Variations(8), BRCA gene mutations in cancer(7), Head and Neck Cancer Studies(6)

Publications84 total

Lentiviral-mediated panErbB CAR-T cell therapy against head and neck squamous cell carcinomas for patients with Fanconi anemia
Molecular Therapy Oncology·2025Open Access
Prognostic significance of mutation type and chromosome fragility in Fanconi anemia
American Journal of Hematology·2024· 12 citedOpen Access
Supplementary Fig. S2 from Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin
2023Open Access
Supplementary Figure 4 from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
2023Open Access
Supplementary Figure 3 from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
2023Open Access
Data from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
2023Open Access
Supplementary Figure 5 from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
2023Open Access
Supplementary Figure 5 from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
2023Open Access
Supplementary Fig. S1 from Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin
2023Open Access
Supplementary Figure 6 from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
2023Open Access
Supplementary Figure 7 from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
2023Open Access
Supplementary Figure 8 from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
2023Open Access
Supplementary Figure 7 from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
2023Open Access
Data from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
2023Open Access
Data from Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin
2023Open Access
Supplementary Fig. S1 from Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin
2023Open Access
Supplementary Figure 2 from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
2023Open Access
Supplementary Text from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
2023Open Access
Supplementary Figure 4 from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
2023Open Access
Supplementary Fig. S2 from Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Juan A. Bueren(39), Jordi Surrallés(29), Paula Rı́o(24), Julián Sevilla(15), José C. Segovia(14), Cristina Díaz de Heredia(13), Marı́a José Ramı́rez(12), Jordi Minguillón(11), Roser Pujol(11), Susana Navarro(10), Helmut Hanenberg(10), Isabel Badell(9), Albert Català(8), Francisco J Roman‐Rodriguez(7), Massimo Bogliolo(6), Rebeca Sánchez‐Domínguez(6), Ricardo López Almaraz(6), Helena Montanuy(6), Águeda Martínez‐Barriocanal(6), Llorenç Rovirosa(6)